Ajinomoto Bio-Pharma Services Competitors and Similar CompaniesClear all
Ajinomoto Bio-Pharma Services's competitors and similar companies include Oxford BioTherapeutics, CytomX Therapeutics, ADC Therapeutics, Lexicon Pharmaceuticals and Anika Therapeutics.
 Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO). |  Oxford BioTherapeutics Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. |  Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. |  Anika Therapeutics Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. | |
Founding Date | Founding Date 1998 | Founding Date 2004 | Founding Date 2008 | Founding Date 2010 | Founding Date 1995 | Founding Date 1992 |
Type | Type Subsidiary | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP | Locations Milton, GB HQ San Jose, US | Locations South San Francisco, US HQ | Locations Epalinges, CH HQ London, GB New Providence, US | Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more | Locations Bedford, US HQ Padova, IT Padova, IT Franklin, US |
Employees | Employees 68610% decrease | Employees 504% increase | Employees 15815% increase | Employees 1162% increase | Employees 20216% increase | Employees 15416% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 78 m | Valuation ($) 295.9 m | Valuation ($) 737.4 m | Valuation ($) 365 m |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) £2.1m (FY, 2018) | Revenue (est.) $76.2m (FY, 2025) | Revenue (est.) $81.4m (FY, 2025) | Revenue (est.) $49.8m (FY, 2025) | Revenue (est.) $112.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $5.1m (FY, 2025) | Cost of goods $274k (FY, 2025) | Cost of goods $49m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $76.3m (FY, 2025) | Gross profit $49.5m (FY, 2025) | Gross profit $63.8m (FY, 2025) |
Net income | Net income N/A | Net income (£6.5m) (FY, 2018) | Net income ($17.4m) (FY, 2025) | Net income ($142.6m) (FY, 2025) | Net income ($50.3m) (FY, 2025) | Net income ($10.9m) (FY, 2025) |
Operating ⚠ | ||||||
Patents (Foreign) | Patents (Foreign) N/A | Patents (Foreign) N/A | Patents (Foreign) 4 (FY, 2016) | Patents (Foreign) N/A | Patents (Foreign) N/A | Patents (Foreign) 151 (FY, 2016) |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) 13 (FY, 2016) | Patents (US) N/A | Patents (US) N/A | Patents (US) 21 (FY, 2016) |
Patents Pending | Patents Pending N/A | Patents Pending N/A | Patents Pending 144 (FY, 2016) | Patents Pending N/A | Patents Pending N/A | Patents Pending 14 (FY, 2016) |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A |
Pre-Clinical Phase Products | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 4 (FY, 2016) | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 1 (FY, 2016) | Pre-Clinical Phase Products N/A |
Funding | ||||||
Total funding raised | Total funding raised $ 3.5m | Total funding raised $ 21.6m | Total funding raised $ 132.4m | Total funding raised $ 526m | Total funding raised $ 244.7m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Oxford BioTherapeutics
HQ
Milton, GB
Employees
50↑ 4% increase
Oxford BioTherapeutics develops medicines for cancer and companion diagnostics for selected antibody programs.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View companyADC Therapeutics
HQ
Epalinges, CH
Employees
116↑ 2% increase
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
View companyLexicon Pharmaceuticals
HQ
The Woodlands, US
Employees
202↑ 16% increase
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
View company